Literature DB >> 28793787

The Roles of NRF2 in Modulating Cellular Iron Homeostasis.

Michael John Kerins1, Aikseng Ooi1.   

Abstract

SIGNIFICANCE: Iron and oxygen are intimately linked: iron is an essential nutrient utilized as a cofactor in enzymes for oxygen transport, oxidative phosphorylation, and metabolite oxidation. However, excess labile iron facilitates the formation of oxygen-derived free radicals capable of damaging biomolecules. Therefore, biological utilization of iron is a tightly regulated process. The nuclear factor (erythroid-derived 2)-like 2 (NRF2) transcription factor, which can respond to oxidative and electrophilic stress, regulates several genes involved in iron metabolism. Recent Advances: The bulk of NRF2 transcription factor research has focused on its roles in detoxification and cancer prevention. Recent works have identified that several genes involved in heme synthesis, hemoglobin catabolism, iron storage, and iron export are under the control of NRF2. Constitutive NRF2 activation and subsequent deregulation of iron metabolism have been implicated in cancer development: NRF2-mediated upregulation of the iron storage protein ferritin or heme oxygenase 1 can lead to enhanced proliferation and therapy resistance. Of note, NRF2 activation and alterations to iron signaling in cancers may hinder efforts to induce the iron-dependent cell death process known as ferroptosis. CRITICAL ISSUES: Despite growing recognition of NRF2 as a modulator of iron signaling, exactly how iron metabolism is altered due to NRF2 activation in normal physiology and in pathologic conditions remains imprecise; moreover, the roles of NRF2-mediated iron signaling changes in disease progression are only beginning to be uncovered. FUTURE DIRECTIONS: Further studies are necessary to connect NRF2 activation with physiological and pathological changes to iron signaling and oxidative stress. Antioxid. Redox Signal. 00, 000-000.

Entities:  

Keywords:  NRF2; cancer; ferroptosis; heme; iron; oxygen

Mesh:

Substances:

Year:  2017        PMID: 28793787      PMCID: PMC6208163          DOI: 10.1089/ars.2017.7176

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  169 in total

1.  Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features.

Authors:  Luisa M Solis; Carmen Behrens; Wenli Dong; Milind Suraokar; Natalie C Ozburn; Cesar A Moran; Alejandro H Corvalan; Shyam Biswal; Stephen G Swisher; B Nebiyou Bekele; John D Minna; David J Stewart; Ignacio I Wistuba
Journal:  Clin Cancer Res       Date:  2010-06-09       Impact factor: 12.531

2.  NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1α.

Authors:  Tae-Hyoung Kim; Eu-gene Hur; Su-Jin Kang; Jung-Ae Kim; Dinesh Thapa; You Mie Lee; Sae Kwang Ku; Yunjin Jung; Mi-Kyoung Kwak
Journal:  Cancer Res       Date:  2011-01-28       Impact factor: 12.701

3.  The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis.

Authors:  Adriana Donovan; Christine A Lima; Jack L Pinkus; Geraldine S Pinkus; Leonard I Zon; Sylvie Robine; Nancy C Andrews
Journal:  Cell Metab       Date:  2005-03       Impact factor: 27.287

4.  Constitutive overexpression of Nrf2-dependent heme oxygenase-1 in A549 cells contributes to resistance to apoptosis induced by epigallocatechin 3-gallate.

Authors:  Mee-Hyang Kweon; Vaqar Mustafa Adhami; Jeong-Sang Lee; Hasan Mukhtar
Journal:  J Biol Chem       Date:  2006-09-01       Impact factor: 5.157

5.  NRF2, a member of the NFE2 family of transcription factors, is not essential for murine erythropoiesis, growth, and development.

Authors:  K Chan; R Lu; J C Chang; Y W Kan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

6.  Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: implication to tumor biology.

Authors:  Yun-Jeong Kim; Ji-Yeon Ahn; Ping Liang; Clement Ip; Yuesheng Zhang; Young-Mee Park
Journal:  Cancer Res       Date:  2007-01-15       Impact factor: 12.701

Review 7.  Oxidative stress in the regulation of normal and neoplastic hematopoiesis.

Authors:  Saghi Ghaffari
Journal:  Antioxid Redox Signal       Date:  2008-11       Impact factor: 8.401

8.  Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy.

Authors:  Tatsuhiro Shibata; Tsutomu Ohta; Kit I Tong; Akiko Kokubu; Reiko Odogawa; Koji Tsuta; Hisao Asamura; Masayuki Yamamoto; Setsuo Hirohashi
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-29       Impact factor: 11.205

9.  Knockdown of Nrf2 suppresses glioblastoma angiogenesis by inhibiting hypoxia-induced activation of HIF-1α.

Authors:  Xiangjun Ji; Handong Wang; Jianhong Zhu; Lin Zhu; Hao Pan; Wei Li; Yuan Zhou; Zixiang Cong; Feng Yan; Suihua Chen
Journal:  Int J Cancer       Date:  2014-01-10       Impact factor: 7.396

10.  hMAF, a small human transcription factor that heterodimerizes specifically with Nrf1 and Nrf2.

Authors:  M G Marini; K Chan; L Casula; Y W Kan; A Cao; P Moi
Journal:  J Biol Chem       Date:  1997-06-27       Impact factor: 5.157

View more
  128 in total

Review 1.  NRF2 and the Hallmarks of Cancer.

Authors:  Montserrat Rojo de la Vega; Eli Chapman; Donna D Zhang
Journal:  Cancer Cell       Date:  2018-05-03       Impact factor: 31.743

Review 2.  Breakdown of an Ironclad Defense System: The Critical Role of NRF2 in Mediating Ferroptosis.

Authors:  Annadurai Anandhan; Matthew Dodson; Cody J Schmidlin; Pengfei Liu; Donna D Zhang
Journal:  Cell Chem Biol       Date:  2020-04-09       Impact factor: 8.116

Review 3.  Iron and magnetic: new research direction of the ferroptosis-based cancer therapy.

Authors:  Shenghang Wang; Jie Luo; Zhihao Zhang; Dandan Dong; Ying Shen; Yanwen Fang; Lijiang Hu; Mengyu Liu; Chengfu Dai; Songlin Peng; Zhicai Fang; Peng Shang
Journal:  Am J Cancer Res       Date:  2018-10-01       Impact factor: 6.166

Review 4.  Crosstalk between Nrf2 signaling and mitochondrial function in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Manuj Ahuja; Bobby Thomas
Journal:  Mol Cell Neurosci       Date:  2019-10-20       Impact factor: 4.314

5.  Differential and overlapping targets of the transcriptional regulators NRF1, NRF2, and NRF3 in human cells.

Authors:  Pengfei Liu; Michael J Kerins; Wang Tian; Durga Neupane; Donna D Zhang; Aikseng Ooi
Journal:  J Biol Chem       Date:  2019-10-18       Impact factor: 5.157

6.  Astragaloside IV inhibits adriamycin-induced cardiac ferroptosis by enhancing Nrf2 signaling.

Authors:  Li-Fei Luo; Peng Guan; Lu-Yun Qin; Jian-Xin Wang; Na Wang; En-Sheng Ji
Journal:  Mol Cell Biochem       Date:  2021-03-03       Impact factor: 3.396

Review 7.  Transferrin receptor 1 in cancer: a new sight for cancer therapy.

Authors:  Ying Shen; Xin Li; Dandan Dong; Bin Zhang; Yanru Xue; Peng Shang
Journal:  Am J Cancer Res       Date:  2018-06-01       Impact factor: 6.166

8.  Pretreatment with Korean red ginseng or dimethyl fumarate attenuates reactive gliosis and confers sustained neuroprotection against cerebral hypoxic-ischemic damage by an Nrf2-dependent mechanism.

Authors:  Lei Liu; Mary K Vollmer; Abdullah S Ahmad; Victoria M Fernandez; Hocheol Kim; Sylvain Doré
Journal:  Free Radic Biol Med       Date:  2018-11-17       Impact factor: 7.376

9.  Nrf2 deficiency in mice attenuates erythropoietic stress-related macrophage hypercellularity.

Authors:  Oluwabukola T Gbotosho; Maria G Kapetanaki; Mark Ross; Samit Ghosh; Frances Weidert; Grant C Bullock; Simon Watkins; Solomon F Ofori-Acquah; Gregory J Kato
Journal:  Exp Hematol       Date:  2020-03-06       Impact factor: 3.084

10.  Cardiac expression of HMOX1 and PGF in sickle cell mice and haem-treated wild type mice dominates organ expression profiles via Nrf2 (Nfe2l2).

Authors:  Oluwabukola T Gbotosho; Samit Ghosh; Maria G Kapetanaki; Yu Lin; Frances Weidert; Grant C Bullock; Solomon F Ofori-Acquah; Gregory J Kato
Journal:  Br J Haematol       Date:  2019-08-06       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.